Currently Viewing:
Newsroom
Currently Reading
ADA 2018 Standards Address Drugs With CV Benefits, Hold Firm on Blood Pressure
December 10, 2017 – Mary Caffrey
UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor
December 08, 2017 – Kelly Davio
5 Approvals and Updates From the FDA This Week
December 08, 2017 – Jaime Rosenberg
AJMC® in the Press, December 8, 2017
December 08, 2017 – AJMC Staff
What We're Reading: Drug Imports; Insurers See ACA Profits; Alzheimer's Forecast
December 08, 2017 – AJMC Staff
This Week in Managed Care: December 8, 2017
December 08, 2017
Company Says It Will Seek FDA Approval for Video Game to Treat ADHD
December 07, 2017 – Allison Inserro
After Years of Research Into Dissatisfaction With Quality Measures, Is CMS Listening?
December 07, 2017 – Allison Inserro
Ribociclib Plus Oral Endocrine Partner Shows Efficacy in Women With HR+/HER2- Breast Cancer
December 07, 2017 – Jaime Rosenberg

What Is the Ideal Age for Screening Mammography?

Surabhi Dangi-Garimella, PhD
According to a new study published in Cancer, an annual screening mammogram starting at age 40 has the greatest impact on reducing mortality.
The conflict over the recommended age for a screening mammogram continues with a new study whose authors conclude that an annual screening starting at age 40 has the greatest impact on reducing mortality.

The study used mean values from 6 Cancer Intervention and Surveillance Modeling Network (CISNET) models to compare 3 recommendations from major healthcare organizations:
  • Annual screening at ages 40 to 84 years
  • Screening annually at ages 45 to 54 years, then biennially at ages 55 to 79 years
  • Biennial screening at ages 50 to 74 years


Per their analysis, the highest reduction in mortality was observed in the cohort that started annual screening at age 40 and continued until age 84 years (mean reduction, 39.6%). The second-highest mortality reduction was observed in the hybrid group (mean reduction 30.8%)—this group initiated their annual screening at age 45 and continued until age 54, followed by biennial screening from 55 to 79. The group that followed the biennial screening recommendation between 50 to 74 years had the lowest reduction in mortality (23.2%).

The analysis showed that for a single-year cohort of women aged 40 years, an annual screening mammogram initiated at age 40 would prevent 29,369 deaths. This compared with 22,829 lives saved for the hybrid screening and 15,599 lives for the biennial screening ages 50 to 74 years (based on 2016 CISNET estimates).

“Our findings are important and novel because this is the first time the 3 most widely discussed recommendations for screening mammography have been compared head to head,” senior author Elizabeth Kagan Arleo, MD, of Weill Cornell Medicine, said in a statement. “Our research would be put to good use if, because of our findings, women chose to start annual screening mammography starting at age 40. Over the long term, this would be significant because fewer women would die from breast cancer.”

Arleo would like women and their physicians to use the findings of this analysis to guide screening choices, with respect to initiation and frequency of screening.

Otis Brawley, MD, FACP, chief medical officer of the American Cancer Society, wrote in an accompanying editorial highlighted the importance on an individual’s value judgement.

“Our goal should be to provide truthful, balanced information so that women can make informed choices about when to start screening for breast cancer. A woman who is making a decision about screening is more interested in her personal chances of benefit and risk of harm and is less interested in the benefits to the population,” he wrote.

His editorial also pointed out the limitations of a mammogram and emphasized the importance of a better test for women that would avoid false positives and be more sensitive.

Reference

Arleo EK, Hendrick R, Helvie MA, and Sickles EA. Comparison of recommendations for screening mammography using CISNET models [published online August 21, 2017]. Cancer. 2017. doi: 10.1002/cncr.30842.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!